

REFERENSI

- Bennis, S., Abbass, F., Akasbi, Y., Znati, K., Joutei, K.A., El Mesbahi, O., 2012. Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study. *BMC Res. Notes* 5, 436.
- Cheang, M., Chia, S., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., 2009. Ki67 Index, HER2 Status, and Prognosis of Patients with Luminal B Breast Cancer. *J Natl Cancer Inst* 101, 736-750.
- Cianfrocca, M., Goldstein, L., 2004. Prognostic and predictive factors in early-stage breast cancer. *Oncologist* 606-616.
- Colzani, E., Liljegren, A., Johansson, A.L. V, Adolfsson, J., Hellborg, H., Hall, P.F.L., Czene, K., 2011. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. *J. Clin. Oncol.* 29, 4014-21.
- Dahlan, M., 2014. *Statistik untuk Kedokteran dan Kesehatan: Deskriptif, Bivariat, dan Multivariat*, 6th ed. Epidemiologi Indonesia, Jakarta.
- Dawson, S., Provenzano, E., Caldas, C., 2009. Triple negative breast cancers: Clinical and prognostic implications. *Eur J Cancer* 45, 27-40.
- Engström, M., Opdahl, S., Hagen, A.I., Romundstad, P.R., Akslen, L.A., Haugen, O.A., Vatten, L.J., Bofin, A.M., 2013. Molecular subtypes , histopathological grade and survival in a historic cohort of breast cancer patients. *Breast Cancer Res Treat* 140, 463-473.
- Gray, M., Gallick, G., 2010. The Role of Oncogenic Activation in Tumor Progression and Mechanisms of Oncogenesis. *USA Springer* 19-22.

- Hammond, M., Hayes, D., Dowsett, M., Allred, D., Hagerly, K., Badve, S., Fitzgibbons, P., Francis, G., Goldstein, N., Hayes, M., Hicks, D., Lester, S., Love, R., Mangu, P., McShane, L., Miller, K., Osborne, C., Paik, S., Perlmutter, J., Rhodes, A., Sasano, H., Schwartz, J., Sweep, F., Taube, S., Torlakovic, E., Valenstein, P., Viale, G., Visscher, D., Wheeler, T., Williams, R., Witliff, J., Wolff, A., 2010. American Society of Clinical Oncology/ College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. *Arch Pathol Lab Med* 907-922.
- Huber, K.E., Carey, L. a, Wazer, D.E., 2009. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. *Semin. Radiat. Oncol.* 19, 204-10.
- Joensuu, K., Leidenius, M., Kero, M., Andersson, L., Horwitz, K., Heikkila, P., 2013. ER, PR, HER2, Ki-67, and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases. *Breast Cancer Basic Clin. Res.* 7, 23-34.
- Kao, K., Chang, K., Hsu, H., Huang, A.T., 2011. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes : implications for treatment optimization. *BMC Cancer* 11, 143.
- Kumar, V., Abbas, A., Aster, J., Robbins, S., 2013. *Robbins Basic Pathology*, 9th ed. Elsevier Inc., Canada.
- Lester, S., 2010. The Breast. In: Vinay, K., Abul K., A., Jon C., A. (Eds.), *Robbins Basic Pathology*. Saunders Elsevier, Philadelphia, pp. 1065-1095.
- Minicozzi, P., Bella, F., Toss, A., Giacomini, A., Fusco, M., Zarcione, M., Tumino, R., Falcini, F., Cesaraccio, R., Candela, G., La Rosa, F., Federico, M., Sant, M., 2013. Relative and disease-free survival for breast cancer in relation to subtype: a population-based study. *J. Cancer Res. Clin. Oncol.* 139, 1569-77.

- Montagna, E., Bagnardi, V., Rotmensz, N., Viale, G., Renne, G., Canello, G., Balduzzi, a, Scarano, E., Veronesi, P., Luini, a, Zurrada, S., Monti, S., Mastropasqua, M.G., Bottiglieri, L., Goldhirsch, a, Colleoni, M., 2012. Breast cancer subtypes and outcome after local and regional relapse. *Ann. Oncol.* 23, 324-31.
- Mukti, A.G., 2012. *Penderita Kanker Diperkirakan Menjadi Penyebab Utama Beban Ekonomi Terus Meningkat*. Pusat Komunikasi Publik, Sekretariat Jenderal Kementerian Kesehatan RI, Yogyakarta.
- Salhia, B., Tapia, C., Ishak, E.A., Gaber, S., Berghuis, B., Hussain, K.H., Duquette, R.A., Resau, J., Carpten, J., 2011. Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. *BMC Women Heal.* 11, 44.
- Santer, Siregar, K., Suyanto, 2011. Profil Ekspresi HER2 dan Ki67 Pada Berbagai Kelompok Usia Penderita Kanker Payudara di RSUP H. Adam Malik Medan.
- Sørli, T., Wang, Y., Xiao, C., Johnsen, H., Naume, B., Samaha, R.R., 2006. Distinct molecular mechanisms underlying clinically relevant different platforms. *BMC Genomic* 7, 127.
- Taneja, P., Maglic, D., Kai, F., Zhu, S., Inoue, K., 2010. Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. *Clin. Med. Insight* 4, 15-34.
- Voduc, K.D., Cheang, M.C.U., Tyldesley, S., Gelmon, K., Nielsen, T.O., Kennecke, H., 2010. Breast cancer subtypes and the risk of local and regional relapse. *J. Clin. Oncol.* 28, 1684-91.
- Walker, R., Barlett, J., Dowsett, M., IO, E., Hanby, A., Jasani, B., Miller, K., Pinder, S., 2008. HER2 Testing in the UK: Further Update to Recommendations. *J Clin Pathol* 61, 818-824.



UNIVERSITAS
GADJAH MADA

**HUBUNGAN ANTARA SUBTIPE MOLEKULAR KARSINOMA PAYUDARA DENGAN STATUS
MORTALITAS DAN KEKAMBUHAN**

MUH. FARID ALIFIAN, dr. Irianiwati, Sp. PA(K); dr. Ahmad Ghozali, Sp. PA(K)

Universitas Gadjah Mada, 2015 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Yerushalmi, R., Wood, R., Ravin, P., 2010. KI 67In
Breast Cancer: Prognostic And Predictive Potential.
Lancet Oncol 11, 174-183.